In this article, we will look at the 10 Best Affordable Growth Stocks to Buy.

On August 30, Anastasia Amoroso, Partners Group chief investment strategist, appeared on CNBC’s ‘Closing Bell’ to talk about the current market dynamics and recent market issues, and much more.

She stated that while the Fed’s independence is an ongoing question, it is not a key driver for the market. According to her, it’s really about whether we get a rate cut in September, and a couple more this year, which is the key determinant.

Amoroso further noted that the second important question is whether the AI momentum is decelerating. She herself does not agree with that, as according to her, the situation is actually the opposite.

READ ALSO: 11 Hot Large Cap Stocks to Buy According to Hedge Funds and 10 High Growth NYSE Stocks That Are Profitable. 

Her take is that she does see the rate cut in September. She further stated that if Trump’s pressure on the Fed continues, one can expect steeper curves, with a higher risk premium in long-duration USTs.

With these trends in view, let’s look at the best affordable growth stocks to buy.

Our Methodology

We used stock screeners to compile a list of growth stocks with a forward P/E below 15 and chose the top 10 most popular among hedge funds, as of Q2 2025. We sourced the hedge fund sentiment data from Insider Monkey’s database. The list is sorted in ascending order of hedge fund holders.

Note: All data was sourced on September 1.

Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).

10 Best Affordable Growth Stocks to Buy

10. Novo Nordisk A/S (NYSE:NVO)

Forward P/E: 14.53

Number of Hedge Fund Holders: 45

Novo Nordisk A/S (NYSE:NVO) is one of the best affordable growth stocks to buy. In a report released on August 29, Matthew Weston from UBS maintained a Hold rating on Novo Nordisk A/S (NYSE:NVO) with a price target of DKK340.00.

Novo Nordisk A/S (NYSE:NVO) announced results for the January 1 to June 30 period on August 6, reporting an operating profit growth of 25% in Danish kroner and 29% at constant exchange rates (CER) to DKK 72.2 billion.

Management also stated that sales in US Operations rose by 16% in Danish kroner (17% at CER), while sales in International Operations grew by 16% in Danish kroner (19% at CER).

Novo Nordisk A/S (NYSE:NVO) is a global healthcare company specializing in diabetes care. It develops, discovers, manufactures, and markets pharmaceutical products.

Its operations are divided into two business segments: biopharmaceuticals and diabetes and obesity care. The latter segment covers GLP-1, insulin, and other protein-related products.

9. Dell Technologies Inc. (NYSE:DELL)

Forward P/E: 12.81

Number of Hedge Fund Holders: 54

Dell Technologies Inc. (NYSE:DELL) is one of the best affordable growth stocks to buy. On August 29, Raymond James raised the firm’s price target on Dell Technologies Inc. (NYSE:DELL) to $152 from $150, keeping an Outperform rating on the shares.

The rating update came after Dell Technologies Inc. (NYSE:DELL) reported a fiscal Q2 beat and increased full-year sales and EPS guidance.

The firm expressed surprise to see that the stock was indicated down about 5% in after-hours. However, it anticipates the shares to recover “once investors absorb all the moving pieces.”

Dell Technologies Inc. (NYSE:DELL) is a technology company that offers customers an innovative and broad solution portfolio to help customers address workforce transformation, modernize their information technology (IT) infrastructure, and offer critical solutions to keep organizations and people connected.

Its operations are divided into the following segments: Infrastructure Solutions Group (ISG) and Client Solutions Group (CSG).

8. Amgen Inc. (NASDAQ:AMGN)

Forward P/E: 13.65

Number of Hedge Fund Holders: 62

Amgen Inc. (NASDAQ:AMGN) is one of the best affordable growth stocks to buy. Leerink Partners analyst David Risinger maintained their neutral stance on Amgen Inc. (NASDAQ:AMGN) on August 26, giving the stock a Hold rating.

The analyst told investors in a research note that he expects the recent approval of Repatha’s expanded label to boost its market penetration, especially in the primary prevention space for cardiovascular events.

However, he added that the current market penetration remains low despite this positive development, with the immediate opportunity depending more on the rising treatment urgency instead of expansion in the patient base.

Amgen Inc. (NASDAQ:AMGN) is a biotechnology company that discovers, develops, manufactures, and markets human therapeutics. It delivers new therapies for patients with complex cancers, especially in areas with significant unmet needs.

7. Schlumberger Limited (NYSE:SLB)

Forward P/E: 12.69

Number of Hedge Fund Holders: 63

Schlumberger Limited (NYSE:SLB) is one of the best affordable growth stocks to buy. On August 20, UBS analyst Josh Silverstein lowered the firm’s price target on Schlumberger Limited (NYSE:SLB) to $44 from $45, keeping a Buy rating on the shares.

The analyst told investors in a research note that persistent commodity headwinds are continually dampening upside potential.

The same day, Melius Research initiated coverage of Schlumberger Limited (NYSE:SLB) with a Buy rating and $82 price target.

The firm told investors in a research note that “Energy & Power” has metamorphosed into an AI category with the introduction, acceleration, and adoption of AI, and that the market is in the early stages of a “Power Revolution.”

The firm is thus establishing coverage on several prominent E&Ps, the Supermajors, the largest independent power producers, and the largest oil services companies.

The stock’s median price target of $36.84 implies an upside of 22.15% from current levels.

Schlumberger Limited (NYSE:SLB) provides energy technology and operates through the following business segments: Digital and Integration, Reservoir Performance, Well Construction, and Production Systems.

6. General Motors Company (NYSE:GM)

Forward P/E: 6.28

Number of Hedge Fund Holders: 71

General Motors Company (NYSE:GM) is one of the best affordable growth stocks to buy. On August 19, Wedbush raised the firm’s price target on General Motors Company (NYSE:GM) to $65 from $55, keeping an Outperform rating on the shares.

The analyst told investors that General Motors Company’s (NYSE:GM) logistics strategies and production relocation should soften the impact of tariffs.

The firm believes that General Motors Company (NYSE:GM) is “embarking down a major path of growth”, supported by a stronger EV market position compared to the last few years and the launch of new models in the coming 6-12 months, catalyzing consumer demand for the company.

However, Wells Fargo analyst Colin Langan maintained a Sell rating on General Motors Company (NYSE:GM) on August 15, setting a price target of $38.00.

General Motors Company (NYSE:GM) is involved in the manufacturing, design, and sale of cars, trucks, crossovers, and automobile parts. It is also involved in the development of autonomous vehicles.

The company also provides software-enabled subscriptions and services, with its operations divided into the following segments: GMNA, GMI, Cruise, and GM Financial.

5. Gilead Sciences, Inc. (NASDAQ:GILD)

Forward P/E: 13.96

Number of Hedge Fund Holders: 71

Gilead Sciences, Inc. (NASDAQ:GILD) is one of the best affordable growth stocks to buy. In a report released on August 21, Evan Seigerman from BMO Capital reiterated a Buy rating on Gilead Sciences, Inc. (NASDAQ:GILD), setting a price target of $130.00.

Similarly, Bernstein raised the firm’s price target on Gilead Sciences, Inc. (NASDAQ:GILD) to $135 from $120 on August 20, keeping an Outperform rating on the shares.

The firm told investors in a research note that Gilead Sciences, Inc. (NASDAQ:GILD) reported EPS and Q2 revenue slightly above estimates, with the full year guidance raised as HIV performed better than expected.

Gilead Sciences, Inc. (NASDAQ:GILD) has a Strong Buy analyst consensus rating, with its median price target of $112.97 implying an upside of 14.19% from current levels.

Gilead Sciences, Inc. (NASDAQ:GILD) is a biotech company that advances medicines to prevent and treat serious diseases such as cancer, immunodeficiency virus (HIV), viral hepatitis, and COVID-19.

Its portfolio of drugs focuses on medical areas with unmet needs and includes AmBisome, Atripla, Biktarvy, Cayston, Complera, and others. Gilead Sciences, Inc. (NASDAQ:GILD) operates in over 35 countries.

4. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Forward P/E: 14.73

Number of Hedge Fund Holders: 73

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the best affordable growth stocks to buy. In a report released on August 27, Cory Kasimov from Evercore ISI maintained a Buy rating on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN), setting a price target of $750.00.

On August 26, Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) reported that its Cemdisiran monotherapy, dosed subcutaneously every three months, met the “primary and key secondary endpoints, showing a 2.3-point placebo-adjusted improvement in Myasthenia Gravis Activities of Daily Living (MG-ADL) total score.”

Management announced that the US regulatory submission for cemdisiran monotherapy is planned for Q1 2026, pending discussions with the FDA.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is a pharmaceutical company that develops, discovers, and commercializes therapies for several diseases, including cancer, eye disorders, and allergic conditions. The company is advancing around 40 of its programs.

It has relied on two primary products to drive top-line growth in the past years: Dupixent and Eylea. Dupixent is an eczema treatment whose rights Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) shares with Sanofi. Eylea, which Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) comarkets with Bayer, treats wet age-related macular degeneration.

3. QUALCOMM Incorporated (NASDAQ:QCOM)

Forward P/E: 13.51

Number of Hedge Fund Holders: 76

QUALCOMM Incorporated (NASDAQ:QCOM) is one of the best affordable growth stocks to buy. On August 26, Arete analyst Brett Simpson upgraded QUALCOMM Incorporated (NASDAQ:QCOM) to Buy from Neutral, setting a $200 price target.

However, Piper Sandler analyst Harsh Kumar lowered the firm’s price target on QUALCOMM Incorporated (NASDAQ:QCOM) to $175 from $190 on July 31, keeping an Overweight rating on the shares.

The firm told investors that QUALCOMM Incorporated (NASDAQ:QCOM) executed well on its diversification plans and is well-positioned for future growth in key areas, including IoT and auto.

QUALCOMM Incorporated (NASDAQ:QCOM) reported its fiscal Q3 2025 results on July 30, with revenue for the quarter reaching $10.4 billion.

The company reported a GAAP EPS of $2.43 and a non-GAAP EPS of $2.77.

QUALCOMM Incorporated (NASDAQ:QCOM) develops and commercializes foundational technologies for the wireless industry, including 3G, 4G, and 5G wireless connectivity and high-performance and low-power computing, including on-device AI.

The company has operations across various high-growth markets, including autonomous vehicles and smartphones. Its Snapdragon augmented reality technology is the next generation of mobile computing. The company continuously innovates to deliver intelligent computing with proven solutions that transform major industries.

2. Merck & Co., Inc. (NYSE:MRK)

Forward P/E: 9.42

Number of Hedge Fund Holders: 92

Merck & Co., Inc. (NYSE:MRK) is one of the best affordable growth stocks to buy. On August 26, Leerink Partners analyst Daina Graybosch maintained a Buy rating on Merck & Co., Inc. (NYSE:MRK) and set a $107.00 price target.

The firm supported the optimistic rating with Merck & Co., Inc.’s (NYSE:MRK) clinical trials, stating that the successful results from the HARMONi-A study reflect the potential of the VEGF-A/PD-(L)1 class for the treatment of particular lung cancer types.

Graybosch added that another significant factor supporting Merck & Co., Inc.’s (NYSE:MRK) positive outlook is the potential for bispecifics to serve as a backbone for novel combinations in global studies. This would position Merck & Co., Inc. (NYSE:MRK) to maximize value.

Merck & Co., Inc. (NYSE:MRK) is a biopharmaceutical company that delivers health solutions to advance the treatment and prevention of diseases in animals and people.

Its Pharmaceutical segment offers vaccines and human health pharmaceutical products, typically therapeutic and preventive agents. Its Animal Health segment develops, discovers, manufactures, and markets a range of vaccines and veterinary pharmaceutical products.

1. Micron Technology, Inc. (NASDAQ:MU)

Forward P/E: 14.73

Number of Hedge Fund Holders: 94

Micron Technology, Inc. (NASDAQ:MU) is one of the best affordable growth stocks to buy. In a new note released on August 27, CLSA analyst Sanjeev Rana initiated coverage on Micron Technology, Inc. (NASDAQ:MU) with an Outperform rating and a price target of $155.

The analyst told investors that he sees Micron Technology, Inc. (NASDAQ:MU) as a primary beneficiary of the growing AI spending, citing steady pricing in DRAM, solid demand for high-bandwidth memory (HBM), and signs of recovery in NAND.

For NAND, the analyst sees signs of recovery with rising demand for enterprise SSDs and a supplier hold-back on aggressive spending.

Rana also stated that Micron Technology, Inc.’s (NASDAQ:MU) pivot towards more customized, AI-focused memory products warrants a higher multiple, setting the company’s price target at 2.4x FY26 book value, a premium to its historical average.

Micron Technology, Inc. (NASDAQ:MU) provides innovative memory and storage solutions. Its operations are divided into the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU).

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.